Neill P. Jakobe
Neill is a co-head of the Private Equity Industry Group at Ropes & Gray, and based in Chicago. Focusing on private equity buyouts and strategic M&A, Neill has helped steer clients through complex deals ranging in size from tens of millions to more than a billion dollars, including more than 15 closed transactions in 2016 alone. Neill’s global client base includes private equity sponsors and public and private companies across various industries, such as health care, life sciences, financial services and manufacturing.
Neill offers clients rare insight into the dealmaking process. In addition to his legal experience structuring, negotiating and closing complex deals, Neill has firsthand transactional experience from his work as an investment banker with the Financial Sponsors Group at Morgan Stanley. He has evaluated acquisitions from a financial perspective, developed financial models, arranged equity and debt financing, and worked on a number of transactions (including IPOs, LBOs and other M&A) on the finance side. Neill’s understanding of the business side of a deal allows him to anticipate his clients’ needs throughout the life cycle of a transaction and take a pragmatic approach in complex negotiations.
Neill’s earlier experience as a securities litigator also benefits clients with corporate governance issues, as he can help identify and analyze the types of securities issues that often lead to litigation in this era of shareholder activism and an activist plaintiffs’ bar. Early in his career, Neill was a member of litigation teams handling high-profile securities fraud matters, including a number of actions arising from the bankruptcy of Enron.
A graduate of the University of Notre Dame and the University of Michigan Law School, Neill has lived and worked in the Midwest for the last 15 years, and he possesses an in-depth knowledge of the region’s private equity and venture capital communities.
- Represented GHO Capital in its (i) acquisition of DNA Diagnostics Centers and (ii) acquisition of Caprion Biosciences.
- Represented Bain and Blackstone in their sale of the digital business of The Weather Company to IBM.
- Represented Cressey and Company in a variety of transactions, including the (i) acquisition of D4C, (ii) acquisition of PurFoods, (iii) sale of VetCor, (iv) sale of Encompass Home Healthcare, (v) sale of Homecare Homebase, and many others.
- Represented Baring Private Equity in a number of transactions, including Baring's (i) investment in St. George's University, (ii) investment in Solera Holdings, (iii) investment in BPO business of Telus International and (iv) IP business of Thomson Reuters.
- Represented BV Investment Partners in a number of matters, including (i) sale of Butterfield Fulcrum group and FORS Limited, (ii) investment in Critical Mix, (iii) investment in geoLogic systems, and (iv) investment in C-4 Analytics.
- Represented Mitsubishi Bank and its affiliates in a variety of transactions, including the (i) acquisition of Meridian Fund Services Group, (ii) acquisition of UBS Global Asset Management's administrative funds business, (iii) Guggenheim's 40 Act fund administration business, and (iv) Neuberger Berman's private equity fund administration business.
- Represented McNally Capital in its (i) acquisition of ITS Logistics, (ii) acquisition of Dedicated Computing, (iii) investment in Genesys Aerosystems and (iv) investment in Europa Sports Products, among other matters.
- Represented Pfingsten Partners in its (i) acquisition and sale of Allied Reliability Group, (ii) sale of Technibus Inc. and (iii) acquisitions of Crane 1 Services.
- Representing HealthSouth Corp. in its acquisition of CareSouth Health System Inc., a private provider of home health services.
- Represented Bain Capital in its majority equity funding of Quva Pharma Inc. and acquisition of 503B assets from Healix Inc.
- Represented Coca Cola Bottling Company in its acquisition of bottling assets and territory rights from Coca Cola Company in Northern Florida, Central Florida and Southern Florida.
- Represented Cressey & Co. in its sale of Strategic Healthcare Programs to Roper Industries.
- Representing Biomet, Inc. in connection with its pending sale to Zimmer Holdings, Inc. for $12.35 billion.
- Represented Nypro, Inc., an employee-owned manufacturing company, in its $665 million sale to Jabil Circuit, Inc.
- Represented Welsh, Carson, Anderson & Stowe and CareSpot in (i) their roll-up of urgent care centers, (ii) investment in Renal Advantage, (iii) sale of Renal Advantage to Liberty Dialysis, (iv) investment in CareSpot and (v) sale of CareSpot.
- Represented TPG in its (i) acquisition of Immucor, Inc., a leading provider of intrument-reagent systems to the blood transfusion industry and (ii) its sale of Fenwal to Fresenius Kabi and (iii) Immucor's acquisitions of the Lifecodes business from Hologic, and the Immucor's acquisitions of Sirona, Organ-I and Sentilus.
- Quoted, “Deal Makers Buoyed After JPMorgan Forum Despite Clouds,” Law360 (January 13, 2017)
- Quoted, “PE Deal Volume Falling As Funds Struggle To Compete,” Law360 (subscription required) (November 19, 2015)
- Quoted, “Second Half PE Forecast: Get In While It’s Hot,” Law360 (July 8, 2014)
- Co-author, “A favourable market for sellers,” Financier Worldwide (June 2014)